{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Although exempted from expedited reporting to Health Authorities and Institutional', 'Review Boards (IRBs) as individual cases, these SAEs must be reported to the Sponsor', 'within 24 hours of the site being made aware of the SAE.', 'AEs or SAEs should not be reported as \"Disease progression,\" even if fatal, as PD is an', 'efficacy endpoint for the study. Rather, report the specific disease (clinical) manifestation', \"of the progression (eg, 'malignant pleural effusion, 'spinal bone metastases,'\", '\\'lymphadenopathy,\\' \\'brain metastases\\') or if not possible, report \"malignant neoplasm', 'progression\" as the AE or SAE as appropriate.', '6.1.2', 'Adverse Event Severity', 'The investigator will rate the severity of each adverse event according to the National', 'Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE', 'Version 4.0). 11 If a reported adverse event increases in severity, the initial adverse event', 'should be given an outcome date and a new adverse event reported on a different date', 'from the end date of the previous adverse event to reflect the change in severity. For all', 'reported serious adverse events that increase in severity, the supplemental eCRFs also', 'need to be updated to reflect the change in severity.', 'When CTCAE criteria cannot be used, the event should be graded as defined below:', 'Grade 1', 'The adverse event is transient and easily tolerated by the subject (mild).', 'Grade 2', 'The adverse event causes the subject discomfort and interrupts the', \"subject's usual activities (moderate).\", 'Grade 3/4', \"The adverse event causes considerable interference with the subject's\", 'usual activities and may be incapacitating or life-threatening (severe).', 'Grade 5', 'The adverse event resulted in death of the subject (severe).', '6.1.3', 'Relationship to Study Drug', 'The investigator will use the following definitions to assess the relationship of the adverse', 'event to the use of blinded investigational products:', '79']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Reasonable', 'After consideration of factors including timing of the event,', 'Possibility', 'biologic plausibility, clinical judgment, and potential alternative', 'causes, there is sufficient evidence (information) to suggest a', 'causal relationship.', 'No Reasonable', 'After consideration of factors including timing of the event,', 'Possibility', 'biologic plausibility, clinical judgment, and potential alternative', 'causes, there is insufficient evidence (information) to suggest a', 'causal relationship.', 'For causality assessments, events assessed as having a reasonable possibility of being', 'related to the study drug will be considered \"associated.\" Events assessed as having no', 'reasonable possibility of being related to study drug will be considered \"not associated.\\'', 'In addition, when the investigator has not reported causality or deemed it not assessable,', 'AbbVie will consider the event associated.', \"If an investigator's opinion of no reasonable possibility of being related to study drug is\", 'given, an Other cause of event must be provided by the investigator for the serious', 'adverse event.', '6.1.4', 'Deaths', 'For SAEs with the outcome of death, the date and cause of death will be recorded on the', 'appropriate case report form.', 'Deaths that occur during the protocol specified AE reporting period (Section 6.1.6) that', 'are more likely related to disease progression will therefore be considered as an expected', 'SAE and will not be subject to expedited reporting. These events should be recorded on', 'the AE eCRF as described in Section 6.1.1.3. After the AE reporting period, deaths', 'attributed to progression of disease under study should not be recorded on the AE eCRF.', 'Death should be considered an outcome and not a distinct event. The event or condition', 'that caused or contributed to the fatal outcome should be recorded as the single medical', 'concept on the AE eCRF. Generally, only one such event should be reported. The term', '\"sudden death\" should only be used for the occurrence of an abrupt and unexpected death', '80']\n\n###\n\n", "completion": "END"}